2,4-diaminopyrimidine derivatives

US7943627B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Rolf Baenteli · Basel, CH
• Gerhard Zenke · Rheinfelden (Baden), DE
• Nigel Graham Cooke · Oberwil, CH
• Rudolf Duthaler · Bettingen, CH
• Gebhard Thoma · Lörrach, DE
• Anette Von Matt · Basel, CH
• Toshiyuki Honda · Tsukuba, JP
• Naoko Matsuura · Tsukuba, JP
• Kazuhiko Nonomura · Tsukuba, JP
• Osamu Ohmori · Tsukuba, JP
• Ichiro Umemura · Tsukuba, JP
• Klaus Hinterding · Kohren-Sahlis, DE
• Christos Papageorgiou · Riedisheim, FR

Key dates

• Filing date: Mar 14, 2003
• Grant date: May 17, 2011
• Expiry date: Aug 19, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There are provided compounds of formula Iwherein X, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as indicated in claim 1, useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.